{"id":535253,"date":"2010-04-20T09:14:03","date_gmt":"2010-04-20T13:14:03","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=74635"},"modified":"2010-04-20T09:14:03","modified_gmt":"2010-04-20T13:14:03","slug":"dyax-in-12m-royalty-deal","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/535253","title":{"rendered":"Dyax in $12M Royalty Deal"},"content":{"rendered":"\n
Life Sciences<\/a>, deals<\/a>, drug discovery<\/a><\/div>\n

\t\tRyan McBride wrote:<\/strong><\/p>\n

Dyax (NASDAQ:DYAX<\/a>), a Cambridge, MA-based biotech company, reports<\/a> today that it has sold its rights to royalties and fees from sales of a hemophilia treatment it discovered to Paul Capital Healthcare for up to $12 million. The deal includes a $10 million upfront payment and up to $2 million in milestone payments tied to\u00a0 sales of the hemophilia treatment in 2010 and 2011. Drug giant Pfizer (NYSE:PFE<\/a>) is commercializing the product, a recombinant Factor VIII therapy, which Dyax discovered with its patented phage display technology.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t\t
\n\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/a>
\n\t\t\t
\n\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, deals, drug discovery Ryan McBride wrote: Dyax (NASDAQ:DYAX), a Cambridge, MA-based biotech company, reports today that it has sold its rights to royalties and fees from sales of a hemophilia treatment it discovered to Paul Capital Healthcare for up to $12 million. The deal includes a $10 million upfront payment and up to […]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-535253","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=535253"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535253\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=535253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=535253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=535253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}